FDA Clears AstraZeneca and Merck’s Lynparza as an Adjuvant Breast Cancer Therapy
The FDA approved the AstraZeneca and Merck drug for a specific group of patients with high-risk early breast cancer after chemotherapy treatment, either before or after surgery. Lynparza cements its position as the best-selling PARP inhibitor with a first-of-its-kind FDA approval.
According to the pharma partners, approximately 91% of all breast cancer patients in the United States are diagnosed at an early stage, with BRCA mutations found in approximately 5% to 10% of cases. Lynparza is the first PARP inhibitor and the first targeted therapy to be approved by the FDA for post...
